Defendant Name: Elanco Animal Health Inc.

Defendant Type: Public Company

Document Reference: 34-104992

Document Details

Legal Case Name In the Matter of Elanco Animal Health Inc.
Document Name Notice of Proposed Plan of Distribution and Opportunity for Comment
Document Date 13-Mar-2026
Document Format Administrative Proceeding
File Number 3-22309
Allegation Type Issuer Reporting and Disclosure
Document Summary The Commission stated: "Notice is hereby given . . . that the Division of Enforcement has submitted to the Commission a proposed plan of distribution (the “Proposed Plan”) for the distribution of monies paid in the above-captioned matter."

Disgorgement & Penalty Information

Resolutions
Cease and Desist Order
Fair Funds
Monetary Penalties:

Civil Penalty

Individual:     $15,000,000.00 Shared:    

Related Documents:

33-11326 12-Nov-2024 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8A of the Securities Act of 1933 and Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order
On November 12, 2024, the SEC instituted settled cease-and-desist proceedings against Elanco Animal Health Inc., stating: "This matter concerns Elanco’s failure to disclose material information concerning its sales practices that rendered statements it made about its revenue growth misleading."
33-11326-s 12-Nov-2024 Administrative Summary
SEC Charges Indiana-Based Animal Health Products Company with Antifraud Violations
On November 12, 2024, the SEC "announced antifraud charges against Elanco Animal Health Inc. for misleading investors when it made statements about its revenue growth and end-user demand without also disclosing its reliance on certain quarter-end sales incentives that were necessary to achieve that revenue and caused its distributors to purchase goods in excess of existing end user demand. Elanco has agreed to pay $15 million to settle the charges."
34-102292 27-Jan-2025 Administrative Proceeding
Extension Order
The Commission ordered that: "the Division’s request for an extension of time until January 21, 2026, to submit a Proposed Plan of Distribution is granted."
34-102489 26-Feb-2025 Administrative Proceeding
Order Appointing Tax Administrator
The Commission ordered that: "Heffler, Radetich & Saitta, LLP is appointed as the Tax Administrator for the QSF in the above-referenced proceeding."
34-104419 17-Dec-2025 Administrative Proceeding
Second Extension Order
The Commission ordered that: "the Division’s request for an extension of time until March 20, 2026, to submit a Proposed Plan of Distribution is granted."
34-104911 02-Mar-2026 Administrative Proceeding
Order Appointing Fund Administrator, Setting Administrator's Bond Amount, and Authorizing the Approval and Payment of the Fees and Expenses of Administration
The Commission ordered that: "A. Epiq is appointed as the Fund Administrator . . . B. Epiq shall obtain a bond . . . in the amount of $15,000,000.00; C. the Fund Administrator will submit invoices to the Commission staff for services rendered . . . and D. at the direction of an Assistant Director of the Office of Distributions, OFM is authorized to pay the Fund Administrator’s fees and expenses from the Fair Fund . . . so long as the total amount paid to the Fund Administrator, including the invoice to be paid, does not exceed the total amount of the approved cost proposal submitted by the Fund Administrator."
34-104992-pdp 13-Mar-2026 Administrative Proceeding
Proposed Plan of Distribution
The Commission stated: "The Division of Enforcement submits this Proposed Plan of Distribution (the “Plan”) to the United States Securities and Exchange Commission (the “Commission”) . . . This Plan provides for the distribution of a Fair Fund (the “Fair Fund”), comprised of civil money penalties collected from Elanco Animal Health Inc. (“Elanco” or the “Respondent”) in the above-captioned matter. . . . the Plan seeks to compensate investors who were harmed by the Respondent’s conduct described in the Order, in connection with Elanco’s failure to disclose material information concerning its sales practices that rendered statements it made about its revenue growth misleading."